Randomised clinical trial: The benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B

M. G. Ghany; J. J. Feld; X. Zhao; T. Heller; E. Doo; Y. Rotman; P. Nagabhyru; C. Koh; D. E. Kleiner; E. C. Wright; T. J. Liang; J. H. Hoofnagle

doi:10.1111/j.1365-2036.2012.05059.x

Randomised clinical trial: The benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B

M. G. Ghany, J. J. Feld, X. Zhao, T. Heller, E. Doo, Y. Rotman, P. Nagabhyru, C. Koh, D. E. Kleiner, E. C. Wright, T. J. Liang, J. H. Hoofnagle

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Background: Combination antiviral therapy holds the promise of increasing response rates while decreasing antiviral resistance, but has yet to be shown to be beneficial or necessary in chronic hepatitis B. Aim: To evaluate the benefit of combination therapy with adefovir and lamivudine versus adefovir alone in maintaining virological, biochemical and histological responses. Methods: Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks. Study endpoints were (i) maintained virological (HBV DNA

Original language	English (US)
Pages (from-to)	1027-1035
Number of pages	9
Journal	Alimentary Pharmacology and Therapeutics
Volume	35
Issue number	9
DOIs	https://doi.org/10.1111/j.1365-2036.2012.05059.x
State	Published - 2012
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1111/j.1365-2036.2012.05059.x

Cite this

Ghany, M. G., Feld, J. J., Zhao, X., Heller, T., Doo, E., Rotman, Y., Nagabhyru, P., Koh, C., Kleiner, D. E., Wright, E. C., Liang, T. J., & Hoofnagle, J. H. (2012). Randomised clinical trial: The benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 35(9), 1027-1035. https://doi.org/10.1111/j.1365-2036.2012.05059.x

Ghany, MG, Feld, JJ, Zhao, X, Heller, T, Doo, E, Rotman, Y, Nagabhyru, P, Koh, C, Kleiner, DE, Wright, EC, Liang, TJ & Hoofnagle, JH 2012, 'Randomised clinical trial: The benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B', Alimentary Pharmacology and Therapeutics, vol. 35, no. 9, pp. 1027-1035. https://doi.org/10.1111/j.1365-2036.2012.05059.x

@article{8b38556e106842d69aa93b492099c85e,

title = "Randomised clinical trial: The benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B",

abstract = "Background: Combination antiviral therapy holds the promise of increasing response rates while decreasing antiviral resistance, but has yet to be shown to be beneficial or necessary in chronic hepatitis B. Aim: To evaluate the benefit of combination therapy with adefovir and lamivudine versus adefovir alone in maintaining virological, biochemical and histological responses. Methods: Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks. Study endpoints were (i) maintained virological (HBV DNA ",

author = "Ghany, {M. G.} and Feld, {J. J.} and X. Zhao and T. Heller and E. Doo and Y. Rotman and P. Nagabhyru and C. Koh and Kleiner, {D. E.} and Wright, {E. C.} and Liang, {T. J.} and Hoofnagle, {J. H.}",

year = "2012",

doi = "10.1111/j.1365-2036.2012.05059.x",

language = "English (US)",

volume = "35",

pages = "1027--1035",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - Randomised clinical trial

T2 - The benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B

AU - Ghany, M. G.

AU - Feld, J. J.

AU - Zhao, X.

AU - Heller, T.

AU - Doo, E.

AU - Rotman, Y.

AU - Nagabhyru, P.

AU - Koh, C.

AU - Kleiner, D. E.

AU - Wright, E. C.

AU - Liang, T. J.

AU - Hoofnagle, J. H.

PY - 2012

Y1 - 2012

N2 - Background: Combination antiviral therapy holds the promise of increasing response rates while decreasing antiviral resistance, but has yet to be shown to be beneficial or necessary in chronic hepatitis B. Aim: To evaluate the benefit of combination therapy with adefovir and lamivudine versus adefovir alone in maintaining virological, biochemical and histological responses. Methods: Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks. Study endpoints were (i) maintained virological (HBV DNA

AB - Background: Combination antiviral therapy holds the promise of increasing response rates while decreasing antiviral resistance, but has yet to be shown to be beneficial or necessary in chronic hepatitis B. Aim: To evaluate the benefit of combination therapy with adefovir and lamivudine versus adefovir alone in maintaining virological, biochemical and histological responses. Methods: Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks. Study endpoints were (i) maintained virological (HBV DNA

UR - http://www.scopus.com/inward/record.url?scp=84860530885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860530885&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2012.05059.x

DO - 10.1111/j.1365-2036.2012.05059.x

M3 - Article

C2 - 22449251

AN - SCOPUS:84860530885

SN - 0269-2813

VL - 35

SP - 1027

EP - 1035

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 9

ER -

Randomised clinical trial: The benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this